Where does RA Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), RA Pharmaceuticals, Inc. ranks #11,050 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does RA Pharmaceuticals, Inc. hold?

RA Pharmaceuticals, Inc. holds 28 US utility patents granted between 2016 and 2025, spanning 9 technology areas.

What is RA Pharmaceuticals, Inc.'s Innovation Score?

RA Pharmaceuticals, Inc. has an Innovation Score of 39.8 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does RA Pharmaceuticals, Inc. focus on?

RA Pharmaceuticals, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 28 patents, ranking #814 of 7,163 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is RA Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

RA Pharmaceuticals, Inc.'s recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for RA Pharmaceuticals, Inc.'s patents?

RA Pharmaceuticals, Inc.'s patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the RA Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

RA Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 28 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, RA ranks #11,050 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 9 technology areas.

#11,050
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.8/100): 18.1
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11050 · US Corporation #11,050 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 28 grants
UPPER-Q #11,050/49,997
PHOTO-FINISH Polares Medical
CPC-NARROW A61K · 9 areas
INNOV-THIN 39.8/100
CLAIMS-RICH 18.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Polares Medical Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How RA’s 39.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.6 pts (29%) Velocity 6.7 pts (17%) Breadth 10.6 pts (27%) Claim depth 10.9 pts (27%)

Qualcomm Incorporated · highest

85
Cellular Research · near

40
Conversant Wireless… · near

40
Green Solution… · near

40
Powerchip Technology · near

40
RA Pharmaceuticals · this assignee

40
3D Lighting… · lowest

7

What this shows RA's Innovation Score is 39.8/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for RA?

Each dot is one of RA’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). RA’s own 18.1 claims/patent is ABOVE the 15.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

RA vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where RA's grants concentrate

RA Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2016. By volume, RA sits between Polares Medical Inc. and Republic Wireless, Inc..

RA's three-year grant acceleration

RA Pharmaceuticals, Inc. shows 11 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Polares Medical

28
Private Identity

28
Protein Metrics

28
Proteus Industries

28
Radiall

28
Raycan Technology…

28
RGB Systems

28
Republic Wireless

28
RA Pharmaceuticals ◀

28

What this shows RA holds 28 patents at rank #11,048, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near RA

By rank, the assignees closest to #11,048 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in RA's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for RA, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), RA ranks #814 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Cellular Research, Inc. 40 Green Solution Technology Co., Ltd. 40 Powerchip Technology Corporation 40 Conversant Wireless Licensing S.à r.l. 40

RA's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

RA Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	3.6%
2017	1	3.6%
2018	3	10.7%
2019	4	14.3%
2020	3	10.7%
2021	4	14.3%
2022	3	10.7%
2023	5	17.9%
2024	3	10.7%
2025partial year	1	3.6%

Which technologies does RA Pharmaceuticals, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 28

C07K - Peptides 24

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 22

Y02A - Technologies FOR Adaptation TO Climate Change 7

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C12Y - Enzymes 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

RA Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

RA Pharmaceuticals, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #11,050 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare RA Pharmaceuticals, Inc. against Polares Medical Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.